The meeting focused on the evaluation of specific bulk drug substances, including Emodelide, Semox, and Epitoilon related substances, for potential inclusion on the 503A bulks list. The committee reviewed the FDA's evaluation criteria, covering physical and chemical characterization, safety, effectiveness, and historical use. Discussions also addressed the role of real-world evidence and clarified alternative pathways for medical access, such as expanded access programs, IND-based clinical trials, and orphan drug designation.
Enterprise
Get verified public-sector contacts at scale
Find verified emails, direct dials, role context, job-change updates, and organization signals across every public-sector account you sell to.
The public hearing focused on the Commissioner’s National Priority Voucher pilot program. Key discussion topics included the program's eligibility criteria, voucher selection processes, sponsor responsibilities, FDA review procedures, and program implementation. Presentations and stakeholder feedback emphasized the importance of streamlined, efficient, and predictable review timelines for innovative therapies addressing serious or rare diseases, alongside requests for clear communication channels and structured engagement opportunities. Participants also discussed the role of data and patient perspectives in informing regulatory decisions.
May 28, 2026·BoardMeeting
Board
Vaccines And Related Biological Products Advisory Committee Meeting
The committee convened to review surveillance and epidemiology data regarding SARS-CoV-2, including the genetic and antigenic characteristics of recent virus isolates. Key discussion topics included the effectiveness of current COVID-19 vaccines and the evaluation of candidate vaccines for the 2026-2027 formula. The committee deliberated on recommendations for the composition of the upcoming COVID-19 vaccine formula for use in the United States, including the potential selection of a JN1 lineage or other variants.
May 4, 2026·BoardMeeting
Board
CDER & CBER All Hands Meeting
The meeting focused on the implementation of the FDA's Plausible Mechanism Framework for individualized medicine. Key discussion topics included the scientific and regulatory strategies for developing targeted therapies for ultra-rare diseases, such as genetic treatments and oligonucleotide therapies. The session provided an update on the treatment of a patient with a urea cycle disorder and outlined the five foundational aspects of the framework: identifying disease abnormalities, developing targeted therapies, leveraging natural disease history, confirming target engagement, and demonstrating improvements in clinical outcomes. The agency discussed its commitment to streamlining the review process for these transformational treatments while maintaining rigorous safety and efficacy standards.
Extracted from official board minutes, strategic plans, and video transcripts.
